NCT02214121 - A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions

Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

Interventions

DRUG

Ticagrelor Dose 1a + Dose 2a

Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.

DRUG

Ticagrelor Dose 1b + Dose 2b

Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.

Trial Locations (18)

100

Research Site, Kisian

1434

Research Site, Tripoli

7500

Research Site, Parow

7700

Research Site, Rondebosch

17022

Research Site, Hershey

19104

Research Site, Philadelphia

29425

Research Site, Charleston

48201

Research Site, Detroit

60612

Research Site, Chicago

92868

Research Site, Orange

M5G 1X8

Research Site, Toronto

Unknown

Research Site, Nairobi

1107 2020

Research Site, Beirut

113-6044

Research Site, Beirut

CF4 4XN

Research Site, Cardiff

E1 1BB

Research Site, London

SE1 7EH

Research Site, London

M13 9PT

Research Site, Manchester